top of page

Making Drugs Work Better™

By using a chemotherapeutic galvanostat/potentiostat (CGP) likeThe Joey from Innovative Potential™, drug molecules work better by affording high-presicion surgical control, expanded reactivity and applications, and increased concentration control over pharmaceutical placement outside of a living body.

Work better is to have external application control over bioactivation.

Why do you want a bioactivateable molecule?

Two reasons:

  1. EAC prefers bioactivatable molecules because EAC will actually toxify (i.e., activate) a non-toxic molecule to make it pharmacologically effective; and,

  2. ​To create molecules with:

  • new mechanisms of action,

  • lower systemic toxicity,

  • lower risk hazard profiles in cases of spills,

  • increased transporation safety,

  • increased shelf-life, or

  • decreased sensitivity to storage conditions.


​​​An ideal EAC drug is:

  • a non-toxic prodrug,

  • only activated by a CGP, like The Joey™,

  • short-lived but stable enough to be pharmacological, and

  • can be stored in fluctuating environmental conditions for a long period of time.

​​​​These qualities make EAC development ideal for cancer treatments, antibiotics, rural markets, pesticides, harsh environments, explosives, and space travel.

Innovative Potential - Plain Logo Plus.png

© Innovative Potential Inc., L.L.C., 2016-2025.

Ab Initio: 1997; A Quo: 2009; Creatum Est: 2016; A Lex: 2017; A Patentatus: 2021; A Genocidio: 2025.
 

All content is authored, and or designed, and or otherwise created, by: Jordache Boudreau, unless otherwise stated.

bottom of page